Completed PHASE3 INTERVENTIONAL 2-arm NCT01760122

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.

Sponsor: Peking University First Hospital

Conditions Chronic Hepatitis B

Interventions Pegasys Ypeginterferon alfa-2b

Updated 6 times since 2017 Last updated: Aug 28, 2015 Started: Mar 31, 2013 Primary completion: Jul 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Hepatitis B, this trial is completed. The trial is conducted by Peking University First Hospital and has accumulated 6 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University First Hospital
Xiamen Amoytop Biotech Co., Ltd.

Data source: Xiamen Amoytop Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Guilin, China , Hangzhou, China , Harbin, China and 16 more locations